Capital Impact Advisors, LLC Bei Gene, Ltd. Transaction History

Capital Impact Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $3.14 Million - $5.06 Million	-12,561 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$292.75 - $367.01 $2.08 Million - $2.61 Million	7,110 Added 130.43%	12,561 $4.31 Million
Q1 2021 May 18, 2021	BUY	$260.64 - $382.12 $1.42 Million - $2.08 Million	5,451 New	5,451 $1.9 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.